New trends on obesity and NAFLD in Asia

Jian Gao Fan, Seung Up Kim, Vincent Wai Sun Wong

Research output: Contribution to journalReview article

125 Citations (Scopus)

Abstract

Traditionally, obesity and its related diseases have been considered a problem in Western countries. However, in the past two decades, urbanisation in many Asian countries has led to a sedentary lifestyle and overnutrition, setting the stage for the epidemic of obesity. This article reviews the epidemiological trend of obesity in Asia, with special emphasis on the emerging condition of non-alcoholic fatty liver disease (NAFLD). Currently, the population prevalence of NAFLD in Asia is around 25%, like many Western countries. While hepatocellular carcinoma and end-stage liver disease secondary to NAFLD remain uncommon, a rising trend has emerged. Around 8–19% of Asians with body mass indexes less than 25 kg/m2 are also found to have NAFLD, a condition often described as “lean” or “non-obese” NAFLD. Although this condition is generally less severe than that in more obese patients, steatohepatitis and fibrotic disease are well recognized. Central adiposity, insulin resistance and weight gain are major risk factors, and genetic predisposition, such as the PNPLA3 polymorphism appears to be more important in the development of NAFLD in the non-obese population. Lifestyle modification remains the cornerstone of management for obesity and NAFLD, but few patients can achieve adequate weight reduction and even fewer can maintain the weight in the long run. While pharmacological agents have entered phase III development for steatohepatitis, Asian patients are under-represented in most drug trials. Future studies should define the optimal management of obesity and NAFLD in Asia.

Original languageEnglish
Pages (from-to)862-873
Number of pages12
JournalJournal of Hepatology
Volume67
Issue number4
DOIs
Publication statusPublished - 2017 Oct

Fingerprint

Obesity
Fatty Liver
Overnutrition
Sedentary Lifestyle
End Stage Liver Disease
Urbanization
Non-alcoholic Fatty Liver Disease
Adiposity
Genetic Predisposition to Disease
Population
Weight Gain
Insulin Resistance
Life Style
Weight Loss
Hepatocellular Carcinoma
Body Mass Index
Pharmacology
Weights and Measures
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Hepatology

Cite this

Fan, Jian Gao ; Kim, Seung Up ; Wong, Vincent Wai Sun. / New trends on obesity and NAFLD in Asia. In: Journal of Hepatology. 2017 ; Vol. 67, No. 4. pp. 862-873.
@article{3e111ce61ce94bc19d438a0c6d4d22fe,
title = "New trends on obesity and NAFLD in Asia",
abstract = "Traditionally, obesity and its related diseases have been considered a problem in Western countries. However, in the past two decades, urbanisation in many Asian countries has led to a sedentary lifestyle and overnutrition, setting the stage for the epidemic of obesity. This article reviews the epidemiological trend of obesity in Asia, with special emphasis on the emerging condition of non-alcoholic fatty liver disease (NAFLD). Currently, the population prevalence of NAFLD in Asia is around 25{\%}, like many Western countries. While hepatocellular carcinoma and end-stage liver disease secondary to NAFLD remain uncommon, a rising trend has emerged. Around 8–19{\%} of Asians with body mass indexes less than 25 kg/m2 are also found to have NAFLD, a condition often described as “lean” or “non-obese” NAFLD. Although this condition is generally less severe than that in more obese patients, steatohepatitis and fibrotic disease are well recognized. Central adiposity, insulin resistance and weight gain are major risk factors, and genetic predisposition, such as the PNPLA3 polymorphism appears to be more important in the development of NAFLD in the non-obese population. Lifestyle modification remains the cornerstone of management for obesity and NAFLD, but few patients can achieve adequate weight reduction and even fewer can maintain the weight in the long run. While pharmacological agents have entered phase III development for steatohepatitis, Asian patients are under-represented in most drug trials. Future studies should define the optimal management of obesity and NAFLD in Asia.",
author = "Fan, {Jian Gao} and Kim, {Seung Up} and Wong, {Vincent Wai Sun}",
year = "2017",
month = "10",
doi = "10.1016/j.jhep.2017.06.003",
language = "English",
volume = "67",
pages = "862--873",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "4",

}

New trends on obesity and NAFLD in Asia. / Fan, Jian Gao; Kim, Seung Up; Wong, Vincent Wai Sun.

In: Journal of Hepatology, Vol. 67, No. 4, 10.2017, p. 862-873.

Research output: Contribution to journalReview article

TY - JOUR

T1 - New trends on obesity and NAFLD in Asia

AU - Fan, Jian Gao

AU - Kim, Seung Up

AU - Wong, Vincent Wai Sun

PY - 2017/10

Y1 - 2017/10

N2 - Traditionally, obesity and its related diseases have been considered a problem in Western countries. However, in the past two decades, urbanisation in many Asian countries has led to a sedentary lifestyle and overnutrition, setting the stage for the epidemic of obesity. This article reviews the epidemiological trend of obesity in Asia, with special emphasis on the emerging condition of non-alcoholic fatty liver disease (NAFLD). Currently, the population prevalence of NAFLD in Asia is around 25%, like many Western countries. While hepatocellular carcinoma and end-stage liver disease secondary to NAFLD remain uncommon, a rising trend has emerged. Around 8–19% of Asians with body mass indexes less than 25 kg/m2 are also found to have NAFLD, a condition often described as “lean” or “non-obese” NAFLD. Although this condition is generally less severe than that in more obese patients, steatohepatitis and fibrotic disease are well recognized. Central adiposity, insulin resistance and weight gain are major risk factors, and genetic predisposition, such as the PNPLA3 polymorphism appears to be more important in the development of NAFLD in the non-obese population. Lifestyle modification remains the cornerstone of management for obesity and NAFLD, but few patients can achieve adequate weight reduction and even fewer can maintain the weight in the long run. While pharmacological agents have entered phase III development for steatohepatitis, Asian patients are under-represented in most drug trials. Future studies should define the optimal management of obesity and NAFLD in Asia.

AB - Traditionally, obesity and its related diseases have been considered a problem in Western countries. However, in the past two decades, urbanisation in many Asian countries has led to a sedentary lifestyle and overnutrition, setting the stage for the epidemic of obesity. This article reviews the epidemiological trend of obesity in Asia, with special emphasis on the emerging condition of non-alcoholic fatty liver disease (NAFLD). Currently, the population prevalence of NAFLD in Asia is around 25%, like many Western countries. While hepatocellular carcinoma and end-stage liver disease secondary to NAFLD remain uncommon, a rising trend has emerged. Around 8–19% of Asians with body mass indexes less than 25 kg/m2 are also found to have NAFLD, a condition often described as “lean” or “non-obese” NAFLD. Although this condition is generally less severe than that in more obese patients, steatohepatitis and fibrotic disease are well recognized. Central adiposity, insulin resistance and weight gain are major risk factors, and genetic predisposition, such as the PNPLA3 polymorphism appears to be more important in the development of NAFLD in the non-obese population. Lifestyle modification remains the cornerstone of management for obesity and NAFLD, but few patients can achieve adequate weight reduction and even fewer can maintain the weight in the long run. While pharmacological agents have entered phase III development for steatohepatitis, Asian patients are under-represented in most drug trials. Future studies should define the optimal management of obesity and NAFLD in Asia.

UR - http://www.scopus.com/inward/record.url?scp=85026462124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026462124&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2017.06.003

DO - 10.1016/j.jhep.2017.06.003

M3 - Review article

C2 - 28642059

AN - SCOPUS:85026462124

VL - 67

SP - 862

EP - 873

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 4

ER -